Collaborations

PRIME is a European consortium of research institutes, medical centres, companies, and societal stakeholders that is funded through an EU Horizon 2020 grant (No 847879). From 2020 – 2024, PRIME aims to unravel the insulin-dependent mechanisms that underly both somatic conditions (i.e. type 2 diabetes, obesity, metabolic syndrome) and brain disorders (i.e. Alzheimer’s disease, obsessive-compulsive disorder, neurodevelopmental disorders). Until now, very little attention has been paid to the role of insulin signaling in brain disorders, and the overlap (or ‘multimorbidity’) with somatic conditions. Through PRIME we aim to develop tools for improved diagnosis, clinical care and prevention of insulin-related lifespan multimorbidity.

Please find more information in the PRIME project Summary and on the project website of PRIME

R2D2-MH is a 5-year project that aims to understand risk and resilience factors associated with mental health and neurodevelopmental diversity. The novelty of R2D2-MH lies in the involvement from start to end of young and adult individuals living with neurodevelopmental diversities, their families, as well as scientists, healthcare givers and industry partners. This approach, called co-creation, will ensure that the project delivers solutions tailored to the needs of the stakeholders. The long-term impact of the project is to shift the paradigm shift, not only by integrating resilience factors to its research approach and tools, but also by redefining wellbeing and functioning. The R2D2-MH project has received funding from Horizon Europe [grant agreement no. 101057385] and from UK Research and Innovation (UKRI) under the UK government’s Horizon Europe funding guarantee [grant no.10039383] (R2D2-MH).

More information about R2D2-MH, please visit the project website.